TP53 and acute myeloid leukemia: In a sensitivity analysis that excluded patients with adverse cytogenetics/TP53-mutated AML, there was a significant differential improvement in the OS rate for GO2, with 5-year OS estimates of 33% vs 26% for GO1 (HR, 0.83 [95% CI, 0.70-1.00]; P = .045; Figure 2B) but not for event-free survival (24% vs 20% for GO1; HR, 0.88 [95% CI, 0.74-1.04]; P = .14).